{
    "nct_id": "NCT02952534",
    "official_title": "TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency",
    "inclusion_criteria": "* Be 18 years old at the time the informed consent form is signed\n* Have a histologically or cytologically confirmed adenocarcinoma or poorly differentiated carcinoma of the prostate\n* Be surgically or medically castrated, with serum testosterone levels of â‰¤ 50 ng/dL (1.73 nM)\n* Experienced disease progression after having received at least 1 but no more than 2 prior next-generation androgen receptor-targeted therapies, and 1 prior taxane-based chemotherapy, for castration-resistant disease\n* Have a deleterious mutation in BRCA1/2 or ATM, or molecular evidence of other homologous recombination deficiency\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active second malignancy, with the exception of curatively treated non-melanoma skin cancer, carcinoma in situ, or superficial bladder cancer\n* Prior treatment with any PARP inhibitor, mitoxantrone, cyclophosphamide or any platinum-based chemotherapy\n* Symptomatic and/or untreated central nervous system metastases\n* Pre-existing duodenal stent and/or any gastrointestinal disorder or defect that would, in the opinion of the investigator, interfere with absorption of rucaparib",
    "miscellaneous_criteria": ""
}